Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 2/20 | 0.72 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.62 |
| ▸ | RARB | P10826 | 3/20 | 0.57 |
| ▸ | THRA | P10827 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.52 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | GALR3 | O60755 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19443009 | 0.84 | PLK1 (0.74) | PLK1TRPV1RARBTHRATHRB | |
| SCHEMBL6919330 | 0.84 | PLK1 (0.74) | PLK1TRPV1RARBTHRATHRB | |
| SCHEMBL6958590 | 0.84 | PLK1 (1.00) | PLK1TRPV1RARBTHRATHRB | |
| SCHEMBL6958582 | 0.82 | PLK1 (0.72) | PLK1TRPV1RARBTHRATHRB | |
| SCHEMBL10949157 | 0.82 | PLK1 (0.72) | PLK1TRPV1RARBTHRATHRB | |
| SCHEMBL10949132 | 0.81 | PLK1 (0.70) | PLK1TRPV1RARBNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL8163518 | 0.81 | PLK1 (0.70) | PLK1TRPV1RARBTHRATHRB | |
| SCHEMBL10948379 | 0.81 | PLK1 (0.70) | PLK1TRPV1RARBTHRATHRB | |
| SCHEMBL7633932 | 0.79 | PLK1 (0.68) | PLK1TRPV1RARBTHRATHRB | |
| SCHEMBL4476375 | 0.79 | RARB (0.62) | PLK1TRPV1RARBTHRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207156-B2 | Substituted pyrazoline compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-26 | — | — | US | disclosed |
| US-20110160181-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160181-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | PIR, SYMPK, P2RX5 | PLK1 905/4885TRPV1 569/4885RARB 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.